A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
University of Minnesota Libraries Publishing
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/d7b83b07b71f43c58222455a5e18945b |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|